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Abstract. Background: A total of 12 piperic acid amides,
including piperine, were subjected to quantitative
structure–activity relationship (QSAR) analysis, based on
their cytotoxicity, tumor selectivity and anti-HIV activity, in
order to find new biological activities. Materials and
Methods: Cytotoxicity against four human oral squamous
cell carcinoma (OSCC) cell lines and three human oral
normal cells was determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Tumor
selectivity was evaluated by the ratio of the mean 50%
cytotoxic concentration (CC50) against normal oral cells to
that against OSCC cell lines. Anti-HIV activity was evaluated
by the ratio of the CC50 to 50% HIV infection-cytoprotective
concentration (EC50). Physicochemical, structural, and
quantum-chemical parameters were calculated based on the
conformations optimized by LowModeMD method followed
by density functional theory method. Results: All compounds
showed low-to-moderate tumor selectivity, but no anti-HIV
activity. N-Piperoyldopamine (8) which has a catechol
moiety, showed the highest tumor selectivity, possibly due to
its unique molecular shape and electrostatic interaction,
especially its largest partial equalization of orbital
electronegativities and vsurf descriptors. Conclusion: The
present study suggests that molecular shape and ability for
electrostatic interaction are useful parameters for estimating
the tumor selectivity of piperic acid amides. 
Piperine {1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]
piperidine)} (Compound 1 in Figure 1), along with its isomer
chavicine, is an alkaloid of black pepper (1). The pungency
of piperine is generated by activating the heat and acidity-
sensing human transient receptor potential vanilloid receptor
(TRPV1) in pain-sensing nerve cells (2). Piperine has been
reported to enhance the oral absorption and hence the
bioavailability of accompanying compounds, possibly by
inhibiting P-glycoprotein-mediated cellular efflux and
cytochrome P450 (CYP) 3A4 (3, 4). Piperine also enhanced
the antimicrobial activity of rifampicin by inhibiting the
multi-drug efflux pump (5). In animal studies, piperine
showed anti-depression/cognitive-enhancing (6), anti-
inflammatory (7) and anti-angiogenic (8) activities. Piperine
also showed mild-to-moderate antibacterial activity against
selected Gram-positive and Gram-negative bacteria (9).
Piperine induced apoptotic cell death in human colon (10),
melanoma cells (11), and lung (12) and rectal carcinoma cell
lines (13), whereas it induced autophagy in human prostate
cancer cells (14), arresting the cells at G0/G1 phase regardless
of the type of cell death (10, 11, 14). Piperine induced
erythroleukemia cells to mature into monocytes/macrophages
(15). On the other hand, piperine protected normal cells
against apoptosis induced by cadmium (16), cisplatin (17) and
glutamate (18). However, rigorous antitumor investigation
with appropriate normal cells from the same tissues or same
type of cells (epithelial or mesenchymal) have not yet been
performed. As far as we know, only one study has reported
that piperine showed no cytotoxicity against WI38 lung
fibroblast as normal counterpart vs. human adenocarcinoma
cell line A549 derived from lung cancer (12). There is no
report on the antiviral activity of piperine. 
In order to discover new biological activities of piperine, a
total of 12 synthetic piperic acid amides including piperine
were investigated for their cytotoxicity and anti-HIV activity,
and then subjected to quantitative structure–activity
relationship (QSAR) analysis. 
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For the cytotoxicity assay, both human normal oral cells
(gingival fibroblast, HGF; periodontal ligament fibroblast,
HPLF; pulp cells, HPC) and human oral squamous cell
carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3,
HSC-4) were used as target cells. The antitumor potential
was evaluated by the tumor-selectivity index (TS),
calculated by dividing the mean 50% cytotoxic
concentration (CC50) against normal oral cells by that
against OSCC cell lines. We have recently reported that
among 24 plant extracts, leaves of Camptotheca acuminate,
a well-known source of camptothecin, had the highest TS
value (88.3) among 24 plant extracts, suggesting that the
TS value determined by this method seems to reflect the
antitumor potential of each plant extract, although these
oral normal and OSCC cell lines of oral origin are
classified as different types of cells (mesenchymal or
epithelial) (19).
For anti-HIV assay, mock- and HIV-infected human T-cell
lymphotropic virus-I (HTLV-I)-carrying human T-cell line
MT4 was used. The selectivity index (SI) was calculated by
diving the CC50 by the 50% HIV infection-cytoprotective
concentration (EC50).
Materials and Methods
Materials. The following chemicals and reagents were obtained
from the indicated companies: Dulbecco’s modified Eagle’s medium
(DMEM), from GIBCO BRL, Grand Island, NY, USA; fetal bovine
serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), azidothymidine and 2’,3’-dideoxycytidine from
Sigma-Aldrich Inc., St. Louis, MO, USA; piperine, dimethyl
sulfoxide (DMSO), dextran sulfate (molecular mass, 5 kDa) from
Wako Pure Chem. Ind., Osaka, Japan; 5-fluorouracil (5-FU) from
Kyowa, Tokyo, Japan; curdlan sulfate (molecular mass, 79 kDa)
from Ajinomoto Co. Ltd., Tokyo, Japan. Culture plastic dishes and
ANTICANCER RESEARCH 34: 4877-4884 (2014)
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Figure 1. Structure of piperic acid amides: piperine {1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]piperidine)} (1) N-Piperoylethanolamine (2),
N-piperoylputrescine (3), N-piperoylcadaverine (4), N-piperoylphenethylamine (5), N-piperoyl-3-phenylpropylamine (6), N-piperoyltyramine (7), N-
piperoyldopamine (8), N-piperoylvanillylamine (9), N-piperoylserotonin (10), N-piperoylhistamine (11) and N-piperoyl-2-(2-pyridinyl)ethylamine (12).
plates (96-well) were purchased from Becton Dickinson Labware
(Franklin Lakes, NJ, USA). 
Synthesis of test compounds. N-Piperoylethanolamine (2), N-
piperoylputrescine (3), N-piperoylcadaverine (4), N-piperoylphe-
nethylamine (5), N-piperoyl-3-phenylpropylamine (6), N-
piperoyltyramine (7), N-piperoyldopamine (8), N-piperoylvanilly-
lamine (9), N-piperoylserotonin (10), N-piperoylhistamine (11) and
N-piperoyl-2-(2-pyridinyl)ethylamine (12) (Figure 1) were
synthesized by coupling of piperic acid with the appropriate amines
by means of a modified procedure described elsewhere (20). To a
mixture of piperic acid (1.0 mmol) in CH2Cl2 (5 ml) was added
oxalyl chloride (10 mmol), and the mixture was stirred at room
temperature for 3 h. The solvent and excess oxalyl chloride were
then evaporated under reduced pressure. The crude acid chloride
generated was dissolved in CH2Cl2 or dimethylformamide (DMF)
(2 ml), and was added dropwise to a mixture of the appropriated
amine or its hydrochloride salt (1.2 mmol) and Et3N (8 mmol) in
CH2Cl2 or DMF (5 ml) under ice-cooling. The reaction mixture
was stirred for 5 h at room temperature. Ice-water was added to the
mixture and the whole was extracted with CHCl3. The organic
layer was dried over Na2SO4 and the solvent was evaporated under
reduced pressure. The residue was then purified by silica gel
column chromatography to give the corresponding piperic acid
amide. All the conjugates were characterized by 1H nuclear
magnetic resonance (NMR) and mass spectrometry (MS) data. All
compounds were dissolved in DMSO at 40 mM and stored at
–20˚C before use. 
Cell culture. HGF, HPLF and HPC cells, established from the first
premolar tooth extracted from the lower jaw of a 12-year-old girl
(21), and OSCC cell lines (Ca9-22, HSC-2, HSC-3, HSC-4),
purchased from Riken Cell Bank, Tsukuba, Japan were cultured at
37˚C in DMEM supplemented with 10% heat-inactivated FBS, 100
units/ml, penicillin G and 100 μg/ml streptomycin sulfate under a
humidified atmosphere with 5% CO2. Cells were then harvested by
treatment with 0.25% trypsin-0.025% EDTA-2Na in phosphate-
buffered saline without calcium and magnesium [PSB(–)] and either
subcultured or used for experiments.
Assay for cytotoxic activity. Cells were inoculated at 2.5×103
cells/0.1 ml in a 96-microwell plate (Becton Dickinson Labware).
After 48 h, the medium was removed by suction with aspirator, and
replaced with 0.1 ml of fresh medium containing different
concentrations of single test compounds. Control cells were treated
with the same amounts of DMSO present in each diluent solution.
Cells were incubated for 48 h, and the relative viable cell number
was then determined by MTT method. In brief, the treated cells
were incubated for another 3 h in fresh culture medium containing
0.2 mg/ml MTT. Cells were then lysed with 0.1 ml of DMSO, and
the absorbance at 540 nm of the cell lysate was determined using a
microplate reader (Biochromatic Labsystem, Helsinki, Finland). The
CC50 was determined from the dose–response curve and the mean
value of CC50 for each cell type was calculated from three
independent experiments. 
Calculation of TS. The TS was calculated by the following equation:
TS=mean CC50 against normal cells/mean CC50 against tumor cells.
Since Ca9-22 cells were derived from gingival tissue (22), the
relative sensitivity of Ca9-22 and HGF was also compared. 
Assay for HIV activity. HTLV-I-carrying human T-cell line MT4
cells (supplied by Dr. Naoki Yamamoto), highly sensitive to Human
Immunodeficiency Virus-1 (HIV-1), were infected with HIV-1IIIB at
a multiplicity of infection (m.o.i.) of 0.01. HIV- and mock-infected
(control) MT-4 cells were incubated for five days with different
concentrations of test compounds and the relative viable cell number
was determined by MTT assay. The CC50 and EC50 were
determined from the dose–response curve for mock-infected and
HIV-infected cells, respectively (23). All data represent the mean
values of triplicate measurements. The anti-HIV activity was
evaluated by SI (CC50/EC50). 
Estimation of CC50 values. Original data contain the sign of
inequality such as”>”. For the convenience of analysis, these values
were changed into forms suitable for arithmetic calculation. Since
“>400” is equal to “from 400 to ∞”, we calculated the harmonic
mean as follows: 1/[average(1/400,1/∞)]=800. Since the CC50 values
had a distribution pattern close to a logarithmic normal distribution,
we used the pCC50 (i.e., the −log CC50) for the comparison of the
cytotoxicity between the compounds. The mean pCC50 values for
normal cells and tumor cell lines were defined as N and T,
respectively (24).
Calculation of the representative value for tumor selectivity. Tumor
selectivity is defined by the balance between pCC50 values for
normal (N) and tumor (T) cells. The difference (T−N) was used as
a tumor-selectivity index only for the following QASR analyses.
Calculation of chemical descriptors. Each chemical structure was
optimized by the LowModeMD method (25), a suitable search
method for minimum energy conformers of flexible molecules, with
Merck Molecular Force Field (MMFF94x) in Molecular Operating
Environment (MOE) 2013.08 (Chemical Computing Group Inc.,
Quebec, Canada). Each structure was refined with density functional
theory (DFT-B3LYP/6-31G**) by using Spartan10 for Windows
(Wavefunction, Inc., Irvine, CA, USA) (26). During each step of the
calculation, quantum chemical, molecular shape, and molecular
property parameters including the partial equalization of orbital
electronegativities (PEOE) and vsurf descriptors, were obtained. The
parameters used were: a_hyd (number of hydrophobic atoms), a_nO
(number of oxygen atoms), logP(o/w) (log of the octanol/water
partition coefficient), logS (log of the aqueous solubility),
PEOE_VSA_FNEG (fractional negative van der Waals surface
area), PEOE_VSA_FPOS (fractional positive van der Waals surface
area), PEOE_VSA_NEG (total negative van der Waals surface area),
PEOE_VSA_PNEG (total negative polar van der Waals surface
area), PEOE_VSA_POL (total polar van der Waals surface area),
PEOE_VSA_PPOS (total positive polar van der Waals surface area),
PEOE_VSA+4 (sum of vi where qi is in the range 0.20-0.25; vi and
qi denote the van der Waals surface area and the partial charge of
atom i, respectively), vsurf_EWmin1 (lowest hydrophilic energy 1),
vsurf_HB6 (H-bond donor capacity 6), vsurf_HB7 (H-bond donor
capacity 7), vsurf_IW7 (hydrophilic interaction-energy moment 7),
vsurf_IW8 (hydrophilic interaction-energy moment 8), vsurf_W7
(hydrophilic volume 7). 
Statistical analysis. The relation among cytotoxicity, tumor-
specificity and chemical descriptors was investigated using simple
regression analyses by JMP Pro version 10.0.2 (SAS Institute Inc.,
Cary, NC, USA). The significance level was set at p<0.05.
Shimada et al: QSAR of Piperic Acid Amides
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Results
Cytotoxicity. Compared to the positive control, 5-FU,
piperine exhibited minor tumor specificity (Table I). Among
11 other analogs, compound [8] exhibited the highest tumor
specificity, whereas other compounds [2-7, 9-12] exhibited
much lower tumor specificity (Table I).
Anti-HIV activity. In contrast to the higher anti-HIV activity
of positive controls (dextran sulfate, curdlan sulfate,
azidothymidine, 2’,3’-dideoxycytidine) (SI=1789-15882),
none of the piperic acid amides 1-12 were able to protect
cells from cytopathic effect of HIV infection (SI<1) (Table
II). Based on these data, the subsequent QSAR analysis was
focused on the cytotoxicity of piperic acid amides. 
Computational analysis. Cytotoxicity of piperic acid amides
against tumor cells (defined by T) correlated with the partial
equalization of orbital electronegativity in total negative van
der Waals surface area (r2=0.751, p<0.0005), fractional
positive van der Waals surface area (r2=0.701. p<0.001),
fractional negative van der Waals surface area (r2=0.701,
p<0.001), log of the octanol/water partition coefficient
(r2=0.492, p<0.05), number of hydrophobic atoms (r2=0.473,
p<0.05) and log of the aqueous solubility (r2=0.432, p<0.05)
(Figure 2A). 
On the other hand, cytotoxicity of piperic acid amides
against normal cells (defined by N) was correlated with
hydrophilic interaction-energy moment 7 (r2=0.530, p<0.01),
lowest hydrophilic energy 1 (r2=0.491, p<0.05), H-bond
donor capacity 7 (r2=0.484, p<0.05), hydrophilic volume 7
(r2=0.484, p<0.05), H-bond donor capacity 6 (r2=0.476,
ANTICANCER RESEARCH 34: 4877-4884 (2014)
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Table I. Cytotoxic activity of twelve piperic acid amides. Each value represents the mean ±S.D. of triplicate assays.
CC50 (μM)
Human oral squamous cell carcinoma cell line Human normal oral cells
Ca9-22 HSC-2 HSC-3 HSC-4 mean±S.D. HGF HPLF HPC mean±S.D. TS
Piperic acid amide (A) (B) (C) (D) (D/B) (C/A)
1 128±14 512±38 583±202 600±24 456±222 473±22 513±13 501±39 496±21 1.1 3.6 
2 239±50 335±54 487±57 450±72 378±113 539±19 510±7.0 518±19 522±15 1.4 2.3 
3 103±15 114±14 134±14 122±11 118±13 81±22 127±1.5 137±13 115±30 1.0 0.8 
4 107±7.6 118±51 170±31 152±18 137±29 122±8.0 137±7.0 131±47 130±7.5 1.0 1.1 
5 7.4±0.8 13±2.1 73±23 199±174 73±89 21±4.0 68±45 82±31 57±32 0.8 2.8 
6 13±4.6 18±7.0 81±2.1 208±88 80±91 16±3.8 41±2.6 19±1.5 25±14 0.3 1.3 
7 11±0.1 16±6.4 18±4.2 14±2.5 15±3.0 13±0.58 23±3.2 20±1.0 19±5.1 1.3 1.2 
8 38±8.5 51±13 131±60 80±17 75±41 >800 >800 >800 >800 >10.7 >21.1
9 79±11 447±331 97±3.2 >800 >356 535±8.7 535±13 573±26 548±22 <1.5 6.8 
10 33±1.2 51±13 38±7.2 58±15 45±12 41±1.7 46±2.3 75±1.2 54±18 1.2 1.2 
11 455±123 696±105 >800 500±53 >613 658±36 617±33 680±41 652±32 <1.1 1.4 
12 183±9.0 262±14 268±6.5 250±3.5 241±39 343±104 497±5.5 467±50 436±82 1.8 1.9 
5-FU 88±11 24±7.8 38±7.6 28±4.9 45±30 >1000 >1000 >1000 >1000 >22.2 >11.4
HGF: Human gingival fibroblast; HPC, human pulp cells; HPLF, human periodontal ligament fibroblast; Ca9-22, HSC-2, HSC-3, HSC-4: human oral
squamous cell carcinoma cell lines; TS: tumor-selectivity index; CC50: 50% cytotoxic concentration; 5-FU: 5-fluorouracil.
Table II. Anti-HIV activity of piperic acid amides and chemotherapeutic
agents. Each value represents the mean of triplicate determinations. 
Piperic acid amides CC50 (μM) EC50 (μM) SI
1 324 >800 <1
2 253 >800 <1
3 112 >800 <1
4 89 >800 <1
5 36 >800 <1
6 279 >800 <1
7 2 >800 <1
8 46 >800 <1
9 688 >800 <1
10 279 >800 <1
11 32 >800 <1
12 175 >800 <1
Positive controls
Dextran sulfate (μg/ml) 621 0.05 12363
Curdlan sulfate (μg/ml) >1000 0.18 5523
Azidothymidine 233 0.015 15882
2’,3’-Dideoxycytidine 2145 1.2 1789
CC50: 50% Cytotoxic concentration; EC50: 50% effective concentration;
SI: selectivity index (CC50/EC50). 
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Figure 2. Correlation coefficient of chemical descriptors and cytotoxicity of piperic acid amides against tumor cells (defined as T) (A) and normal cells
(defined as N) (B). The mean (pCC50 i.e, the −log CC50) values for normal cells and tumor cell lines were defined as N and T, respectively. The
descriptors used were: a_hyd (Number of hydrophobic atoms), logP(o/w) (Log of the octanol/water partition coefficient), logS (Log of the aqueous
solubility), PEOE_VSA_FNEG (Fractional negative van der Waals surface area), PEOE_VSA_FPOS (Fractional positive van der Waals surface area),
PEOE_VSA_NEG (Total negative van der Waals surface area), vsurf_EWmin1 (Lowest hydrophilic energy 1), vsurf_HB6 (H-bond donor capacity 6),
vsurf_HB7 (H-bond donor capacity 7), vsurf_IW7 (Hydrophilic interaction-energy moment 7), vsurf_W7 (Hydrophilic volume 7).
p<0.05) and total positive polar van der Waals surface area
(r2=0.425, p<0.05) (Figure 2B).
Tumor selectivity of piperic acid amides (defined by T–
N) correlated with the vsurf descriptor in standard
hydrophilic interaction-energy moment 8 (vsurf_IW)
(r2=0.638, p<0.005), the partial equalization of orbital
electronegativity in total polar van der Waals surface area
(r2=0.609, p<0.005), sum of van der Waals surface area in
atoms with the partial charge (r2=0.583, p<0.005), fractional
positive van der Waals surface area (r2=0.583, p<0.005),
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Figure 3. Correlation coefficient of chemical descriptors and tumor specificity of piperic acid amides, defined as T−N. The descriptors used were: a_nO
(Number of oxygen atoms), PEOE_VSA_PNEG (Total negative polar van der Waals surface area), PEOE_VSA_POL (Total polar van der Waals surface
area), PEOE_VSA_PPOS (Total positive polar van der Waals surface area), PEOE_VSA+4 (Sum of vi where qi is in the range [0.20,0.25]; vi and qi
denote the van der Waals surface area and the partial charge of atom i, respectively), vsurf_IW8 (Hydrophilic interaction-energy moment 8).
total negative polar van der Waals surface area (r2=0.519,
p<0.01) and number of oxygen atoms (r2=0.467, p<0.05)
(Figure 3).
Discussion
The present study demonstrated for the first time that
piperine has minor antitumor potential but no anti-HIV
activity, and introduction of a catechol moiety [8]
significantly enhanced the tumor specificity. We found that
TS values determined by two different equations (either D/B
or C/A, see Table I) were considerably variable, suggesting
the considerable difference in sensitivity of seven cell lines
used to the 12 piperic acid amide derivatives. It is, thus,
necessary that we should use more than three cell lines for
both normal and tumor cell groups. Based on these
experimental data, we performed the QASR analysis using
the D/B value.
We could not obtain significant descriptors for T from the
quantum chemical approaches. Therefore, with the
assistance of descriptors calculated by MOE, a total 330
parameters were searched. We found that many PEOE
descriptors, which provide information on electric charge,
and vsurf descriptors, which reflect the molecular shape,
explain well the cytotoxicity and tumor-selectivity of piperic
acid amides. The PEOE method of calculating atomic partial
charges (27) is a method in which charge is transferred
between bonded atoms until equilibrium. The vsurf
descriptors are similar to the VolSurf descriptors (28), and
depend on the structure connectivity and conformation. We
found good correlation of T with van der Waals surface area
(total negative, fractional positive and negative) and
hydrophobic property (Figure 2A). N correlated well with
hydrophilic interaction-energy moment and energy, H-bond
donor capacity and volume, and total positive polar van der
Waals surface area (Figure 2B). The tumor selectivity (T−N)
correlated well with van der Waals surface area (total polar,
positive polar and negative polar), and number of oxygen
atoms (Figure 3). Compound [8] had the highest tumor
specificity, possibly due to its unique molecular shape and
electrostatic interaction, especially its largest PEOE and
vsurf descriptors. 
Curcumin (diferuloylmethane), a natural compound
extracted from Curcuma longa L, has been reported by
many investigators to inhibit the proliferation of various
tumor cells in culture, prevent carcinogenesis and inhibit
the growth of implanted tumors (29). However, the
evaluation system used herein for TS demonstrated that
curcumin had a very narrow therapeutic window (TS=1.7)
(30). Previous attempts to enhance the antitumor potential
of curcumin by introducing piperic acid and glycine (31) or
demethoxy, bisdemethoxy or piperoyl (32) groups were
unsuccessful. 
In conclusion, the present study demonstrates there are
many chemical descriptors specific to cytotoxicity against
normal and tumor cells, and TS. Tumor selectivity was well-
correlated with molecular shape and electrostatic interaction.
Multivariate statistics with these chemical descriptors may
be useful for designing the most favorable compound with
higher tumor selectivity.
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